samedan logo
 
 
 
spacer
home > pmps > winter 2016 > industry insight
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Industry Insight

One third of the planet’s population lacks access to essential medicines. As one of its millennium development goals, the WHO is striving to improve the availability of affordable drugs for the world’s poor (1). Together with governments and pharmaceutical companies, the WHO is working on making basic medicines accessible to those who most need them, particularly infants and the elderly in developing nations. Achieving this is one thing, but the storage and distribution of drugs in remote areas of the globe can turn into a nightmare.

It is a sobering fact that although basic and much-needed medicines are often in short supply to those living in the poorest regions of the world, a wellknown soft drink product can easily be found – even in the most remote locations. In this edition, Jane Berry describes how UK charity ColaLife has taken advantage of ‘piggy-backing’ the distribution networks of a soft drink giant to distribute kits for treatment With the new year upon us, manufacturers are busy designing and developing solutions for the pharmaceutical packaging and drug delivery sectors, amidst an increasingly competitive landscape. Scheduled in the first quarter of the year are a series of important exhibitions. PMPS will be out and about in early February at Pharmapack Europe in Paris, France – a big event in our calendar and hopefully in yours too. This edition features a wide range of packaging and manufacturing-related articles to tie in with the show. Watch out for us at the RDD conference in Phoenix, Arizona too – held 17-21 April 2016 – where we’ll be promoting our new Inhalation Technology Supplement. If you missed the last issue of PMPS – offering articles on auto-injection devices, eSubmissions and temperature-controlled packaging – you can still access the digital version at www.samedanltd.com, or download the Samedan App to browse previous editions on the go. Coming up in the Spring is a very special edition. Ahead of our second FlyPharma of diarrhoea to children across Zambia (page 22 of the article PDF). There surely must be great opportunities for other essential medicines to be allocated using the help of fast-moving consumer goods organisations.

For those drugs that are available in developing countries, there is then the question of whether they might be real or counterfeit. Falsified medicines afflict all global regions, but the problem is worse in developing regions, with up to 70% of pharmaceuticals in some African and Eastern European states being counterfeit. Ian Lemon from Essentra outlines current developments in serialisation, which aim to protect the integrity of medical products and ensure the security of the supply chain (page 28 of the article PDF).

PMPS also features articles relating to product design initiatives within pharma. Augment’s Lindsay Boyajian provides a fascinating insight into developments in pack design, where virtual images of potential products can be seamlessly blended into real life images (page 12). This augmented reality facilitates packaging assessment through virtual imagery rather than by manufacture of expensive mock-ups. Jérôme Empereur at Stiplastics also discusses the difficulties in assuring that medicines are used properly and the initiatives he hopes will lead to greater patient compliance (page 18 of the article PDF).

Lastly, in this month’s issue we include a new Inhalation Technology Supplement, containing a selection of articles about this unique sector. You’ll find content on everything from inhaled generics testing to patient adherence, plus a preview of the forthcoming Respiratory Drug Delivery events in Phoenix, Goa and Nice from co-organiser, Richard Dalby.

Reference
1. Access indicators developed by WHO. Visit: www.un.org/esa/policy/ mdggap/appendix.pdf

With the new year upon us, manufacturers are busy designing and developing solutions for the pharmaceutical packaging and drug delivery sectors, amidst an increasingly competitive landscape.

Scheduled in the first quarter of the year are a series of important exhibitions. PMPS will be out and about in early February at Pharmapack Europe in Paris, France – a big event in our calendar and hopefully in yours too. This edition features a wide range of packaging and manufacturing-related articles to tie in with the show.

Watch out for us at the RDD conference in Phoenix, Arizona too – held 17-21 April 2016 – where we’ll be promoting our new Inhalation Technology Supplement.

If you missed the last issue of PMPS – offering articles on auto-injection devices, eSubmissions and temperature-controlled packaging – you can still access the digital version at www.samedanltd.com, or download the Samedan App to browse previous editions on the go.

Coming up in the Spring is a very special edition.  Ahead of our second FlyPharma Conference – taking place 7-8 June 2016 in Brussels, Belgium – PMPS May will introduce a number of themes up for debate at the event, including collaboration, serialisation and supply chain security. Find out more about FlyPharma on pages 38-39.

Stay tuned to the latest news and updates by following us on Twitter @PMPSmag, or email me if you’d like to contribute at angela@samedanltd.com.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

SGD Pharma introduces Ensiemo, the new complete child-resistant packaging solution for CBD oils

SGD Pharma today announces the launch of its new full packaging solution dedicated to the cannabidiol (CBD) oil market. Combining the company’s extensive pharmaceutical packaging expertise with the need for compliant, safe packaging for CBD oils, SGD Pharma has developed Ensiemo – a glass dropper and bottle offering that meets international regulatory standards.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement